Nanoengineering strategies for precision regulation of chimeric antigen receptor T-cell-induced cytokine release syndrome.
Abstract
Chimeric antigen receptor (CAR)-T cell therapy faces a critical clinical hurdle: cytokine release syndrome (CRS). Current CRS management strategies have limited selectivity and may interfere with CAR-T cell antitumor activity, highlighting the need for more targeted and precisely controllable interventions. Nanoengineering offers a promising approach to address these limitations by enabling the spatiotemporally controlled monitoring and modulation of inflammatory responses, with the potential to mitigate excessive cytokine release while preserving CAR-T cell therapeutic efficacy, driving a paradigm shift toward programmable, proactive immune regulation. This review systematically examines nanointervention strategies for mitigating CAR-T-induced CRS, including molecular monitoring, cytokine clearance, targeted delivery, stimulus-responsive systems, biomimetic designs, and genetic reprogramming. These approaches enable precise intervention across multiple stages-from early inflammation detection and localized neutralization to source-level cellular engineering. Finally, we discuss challenges in biosafety, clinical translation, and the potential of artificial intelligence-driven predictive platforms. Nanotechnology offers a transformative pathway to redefine CRS from an unpredictable complication into a manageable therapeutic window, paving the way for safer next-generation cellular immunotherapies.